Ignite Creation Date:
2025-12-25 @ 12:40 AM
Ignite Modification Date:
2026-01-25 @ 11:09 PM
Study NCT ID:
NCT01499667
Status:
TERMINATED
Last Update Posted:
2014-08-08
First Post:
2011-08-18
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
Sponsor:
Novartis Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CFTY720D2324
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None